



Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer

Laura W. Goff^{1,2} · Nilofer S. Azad³ · Stacey Stein⁴ · Jennifer G. Whisenant^{1,2} · Tatsuki Koyama^{1,5} · Ulka Vaishampayan⁶ · Howard Hochster⁷ · Roisin Connolly³ · Amy Weise⁶ · Patricia M. LoRusso⁴ · Safia N. Salaria¹ · Wael El-Rifai⁸ · Jordan D. Berlin^{1,2}

Published online: 18 October 2018

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Correction to: *Investigational New Drugs*

<https://doi.org/10.1007/s10637-018-0663-0>

The authors would like to note that the investigator affiliations have been corrected to reflect the actual affiliations of each author. The authors would also like to note an amendment to the first name of the second author: Nilo Azad was changed to reflect the full name of the author, which is Nilofer S. Azad as shown above.

The original article has been corrected.

The online version of the original article can be found at <https://doi.org/10.1007/s10637-018-0663-0>

✉ Laura W. Goff
laura.goff@vumc.org

¹ Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Vanderbilt University, 2220 Pierce Avenue, PRB 777, Nashville, TN 37232, USA

² Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

³ Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

⁴ Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA

⁵ Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA

⁶ Karmanos Cancer Institute, Detroit, MI, USA

⁷ Rutgers Cancer Institute, New Brunswick, NJ, USA

⁸ University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA